166 related articles for article (PubMed ID: 10395861)
1. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors.
Cassone A; De Bernardis F; Torosantucci A; Tacconelli E; Tumbarello M; Cauda R
J Infect Dis; 1999 Aug; 180(2):448-53. PubMed ID: 10395861
[TBL] [Abstract][Full Text] [Related]
2. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.
Gruber A; Berlit J; Speth C; Lass-Flörl C; Kofler G; Nagl M; Borg-von Zepelin M; Dierich MP; Würzner R
Immunobiology; 1999 Sep; 201(1):133-44. PubMed ID: 10532286
[TBL] [Abstract][Full Text] [Related]
3. [Highly Active AntiRetroviral Therapy and cryptosporidiosis].
Morales Gomez MA
Parassitologia; 2004 Jun; 46(1-2):95-9. PubMed ID: 15305695
[TBL] [Abstract][Full Text] [Related]
4. Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors.
Migliorati CA; Birman EG; Cury AE
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Sep; 98(3):301-10. PubMed ID: 15356467
[TBL] [Abstract][Full Text] [Related]
5. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients.
Korting HC; Schaller M; Eder G; Hamm G; Böhmer U; Hube B
Antimicrob Agents Chemother; 1999 Aug; 43(8):2038-42. PubMed ID: 10428932
[TBL] [Abstract][Full Text] [Related]
6. HIV protease inhibitors differentially inhibit adhesion of Candida albicans to acrylic surfaces.
Tsang CS; Hong I
Mycoses; 2010 Nov; 53(6):488-94. PubMed ID: 19538521
[TBL] [Abstract][Full Text] [Related]
7. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
Sobel JD; Ohmit SE; Schuman P; Klein RS; Mayer K; Duerr A; Vazquez JA; Rampalo A;
J Infect Dis; 2001 Jan; 183(2):286-93. PubMed ID: 11204125
[TBL] [Abstract][Full Text] [Related]
8. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
9. Anti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo by Candida albicans without selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility.
De Bernardis F; Tacconelli E; Mondello F; Cataldo A; Arancia S; Cauda R; Cassone A
FEMS Immunol Med Microbiol; 2004 May; 41(1):27-34. PubMed ID: 15094164
[TBL] [Abstract][Full Text] [Related]
10. The inhibition of Candida-albicans-secreted aspartic proteases by three different HIV protease inhibitors.
Monod M; Borg-von Zepelin M; Telenti A; Sanglard D
Dermatology; 1999; 198(4):412-4. PubMed ID: 10490300
[No Abstract] [Full Text] [Related]
11. In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii.
Atzori C; Angeli E; Mainini A; Agostoni F; Micheli V; Cargnel A
J Infect Dis; 2000 May; 181(5):1629-34. PubMed ID: 10823762
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects.
Cassone A; Tacconelli E; De Bernardis F; Tumbarello M; Torosantucci A; Chiani P; Cauda R
J Infect Dis; 2002 Jan; 185(2):188-95. PubMed ID: 11807692
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro.
Gruber A; Speth C; Lukasser-Vogl E; Zangerle R; Borg-von Zepelin M; Dierich MP; Würzner R
Immunopharmacology; 1999 Apr; 41(3):227-34. PubMed ID: 10428651
[TBL] [Abstract][Full Text] [Related]
14. The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen Cryptococcus neoformans.
Blasi E; Colombari B; Orsi CF; Pinti M; Troiano L; Cossarizza A; Esposito R; Peppoloni S; Mussini C; Neglia R
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):187-95. PubMed ID: 15364103
[TBL] [Abstract][Full Text] [Related]
15. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro.
Bektić J; Lell CP; Fuchs A; Stoiber H; Speth C; Lass-Flörl C; Borg-von Zepelin M; Dierich MP; Würzner R
FEMS Immunol Med Microbiol; 2001 Jul; 31(1):65-71. PubMed ID: 11476984
[TBL] [Abstract][Full Text] [Related]
16. HIV-Protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases.
Borg-von Zepelin M; Meyer I; Thomssen R; Würzner R; Sanglard D; Telenti A; Monod M
J Invest Dermatol; 1999 Nov; 113(5):747-51. PubMed ID: 10571729
[TBL] [Abstract][Full Text] [Related]
17. Changes in oropharyngeal colonization and infection by Candida albicans in human immunodeficiency virus-infected patients.
Diz Dios P; Ocampo A; Otero I; Iglesias I; Martínez C
J Infect Dis; 2001 Jan; 183(2):355-356. PubMed ID: 11120936
[No Abstract] [Full Text] [Related]
18. Differential expression of secretory aspartyl proteinase genes (SAP1-10) in oral Candida albicans isolates with distinct karyotypes.
Tavanti A; Pardini G; Campa D; Davini P; Lupetti A; Senesi S
J Clin Microbiol; 2004 Oct; 42(10):4726-34. PubMed ID: 15472333
[TBL] [Abstract][Full Text] [Related]
19. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.
Crommentuyn KM; Mulder JW; Sparidans RW; Huitema AD; Schellens JH; Beijnen JH
Clin Infect Dis; 2004 Apr; 38(8):e73-5. PubMed ID: 15095234
[TBL] [Abstract][Full Text] [Related]
20. Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA).
Vazquez JA; Sobel JD; Peng G; Steele-Moore L; Schuman P; Holloway W; Neaton JD
Clin Infect Dis; 1999 May; 28(5):1025-31. PubMed ID: 10452629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
